Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies



Rating:

Share or cite this content

Citations should be made in the following way:
M. van der Schee (Amsterdam, Netherlands). Early detection of lung cancer through analysis of VOC biomarkers in exhaled breath: The LuCID study.. 1472

Member's Comments

No comment yet.

Related content which might interest you: Exhaled biomarkers in lung cancer Source: Eur Respir J 2009; 34: 261-275 Year: 2009 Better characterization of local inflammation in COPD: detection of new biomarkers in exhaled breath condensate Source: Eur Respir J 2006; 28: Suppl. 50, 747s Year: 2006 Lung disease diagnostic method based on proteomic analysis of exhaled breath condensate Source: International Congress 2019 – Basic research of airway diseases Year: 2019 Dermcidin identification from exhaled air for lung cancer diagnosis Source: Eur Respir J 2010; 35: 1182-1185 Year: 2010 Detection of lung cancer by analysis of exhaled breath: from sniffing dogs to modern mass-spectrometric techniques Source: Annual Congress 2013 –Early detection of lung cancer Year: 2013 Differences in volatile organic compounds (VOC) determined in exhaled breath in two populations of lung cancer (LC): With and without COPD Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Exhaled breath condensate sample collection: standards and open issues Source: Eur Respir Monogr 2010; 49: 152-161 Year: 2010 Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 Diagnosis of lung diseases based on proteomic analysis of exhaled breath condensate Source: International Congress 2017 – Clinical problems in lung diseases Year: 2017 Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease Source: Eur Respir J, 57 (1) 2002042; 10.1183/13993003.02042-2020 Year: 2021 The clinical significance of growth factors measurement in exhaled breath condensates (EBC) among patients with interstitial lung diseases Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD Source: Eur Respir J 2011; 38: 1301-1309 Year: 2011 Metabolomic/proteomic analysis of biomarkers in exhaled breath condensates Source: Annual Congress 2008 - PG8 - Cellular and molecular technologies of today - treatments of tomorrow Year: 2008 The validation of assays used to measure biomarkers in exhaled breath condensate Source: Eur Respir J 2008; 32: 1408-1409 Year: 2008 Exhaled breath condensate biomarkers in COPD Source: Eur Respir J 2008; 32: 472-486 Year: 2008 Using exhaled breath profiles in the discrimination between COPD, lung cancer and their co-morbidity Source: International Congress 2015 – Developments in lung cancer diagnosis Year: 2015 Protein markers in the exhaled breath condensate of lung carcinoma patients Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases Year: 2012 Is the analysis of torbamycin in exhaled breath condensate a diagnostic tool to monitor pulmonary drug deposition? Source: Eur Respir J 2004; 24: Suppl. 48, 386s Year: 2004 Analysis of exhaled air for a rapid, sensible and specific diagnosis of COPD Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015 Early detection of lung cancer in exhaled breath condensate using miRNA markers Source: International Congress 2015 – Developments in lung cancer diagnosis Year: 2015